Gabapentin and pregabalin with opioids: Increased overdose risk in Canada
In plain language
Health Canada is advising Canadians about the increased risk of opioid overdose and serious side effects when taking gabapentin or pregabalin with an opioid. This advisory is for drugs like gabapentin (e.g., Neurontin) and pregabalin (e.g., Lyrica) when used with opioids. Serious side effects include slowed breathing, increased sleepiness, dizziness, fainting, and death. Consult your healthcare practitioner if you are concerned.
What to do
- Consult your healthcare practitioner if you currently use or have used gabapentinoids or opioids.
- Know the signs of an opioid overdose.
- Stay informed about other drugs and substances that can increase overdose risk when mixed with opioids.
- Report suspected adverse reactions to Health Canada.
Get alerts for recalls like this
Get email alerts when new recalls affect products in this category.
Affected products
Specific affected products are listed in the official notice.
Why this matters
Increased risk of opioid overdose and serious side effects, including death
Do I have this product?
This recall applies to specific products. Details are listed in the official notice.
Frequently Asked Questions
Why was this product recalled?
Increased risk of opioid overdose and serious side effects, including death
What should consumers do?
Consult your healthcare practitioner if you currently use or have used gabapentinoids or opioids. Know the signs of an opioid overdose. Stay informed about other drugs and substances that can increase overdose risk when mixed with opioids. Report suspected adverse reactions to Health Canada.
Where was the product sold?
This product was sold in Canada. For specific retailers or distribution areas, please check the official recall notice linked on this page.
Is there a health risk?
Yes, there may be a health risk. Increased risk of opioid overdose and serious side effects, including death
When was this product recalled?
This product was recalled on September 17, 2019.